If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A French pre-clinical stage start-up develops novel solutions to treat neurodegeneration, a process linked with microtubule disorders. It develops compounds to restore microtubule stability. One application is stopping neurodegeneration of the optic nerve in glaucoma, the leading cause of irreversible blindness. The company seeks partners specialized in biopolymers and/or surface chemistry to develop drug formulation and delivery solutions into the eye under research or technical agreements.
In view of the ageing population, finding a cure for glaucoma, the first cause of irreversible blindness worldwide, remains a priority challenge of the EU.
Glaucoma is the result of neurodegeneration of the ganglionic cells of the optical nerve and is accompanied by an increase of the intra-ocular pressure within the eye cavity. While drugs that stabilize and or reduce intra-ocular pressure are quite efficient, it does not always stop neurodegeneration. In glaucoma models, dissociation of the microtubule associated protein tau from microtubules, was recently shown to be linked to the degenerative process. There is a single molecule on market, brimonidine, which beneficial effects remain controversial. While current pharmaceutical efforts focus on acting on tau itself, therapeutics that target the enzymes modifying the microtubules, have so far never been explored. In turn, the company develops compounds to prevent tau dissociation and restore its binding to microtubules. The solutions developed by the company are therefore unique in the healthcare landscape and open the road to novel class of medication
Based on breakthrough discoveries, proprietary technologies and unique expertise, the French company has developed first-in-class compounds that specifically target microtubule modifying enzymes. These compounds regulate the biophysical properties of the microtubule surface to favorize the binding of structural microtubule associated proteins and hence promote neuroprotection. The novel compounds that have been developed are aimed at stopping the process of neurodegeneration within the optic nerve, by targeting microtubule modifications.
SMEs and pharma industries specialized in biopolymers and/or surface chemistry are sought to contribute to develop and improve drug formulation and delivery solutions into the eye. The idea is to attach the compounds to matrices that allow efficient drug delivery intravitreally and follow the outcome in appropriate models to obtain proof of concepts.
According to the stage of development of the delivery system of the partner, research agreements for co-development or technical agreements in case of use of an existing solution will be made.
The start-up company is looking for a drug delivery vessel (natural or synthetic biopolymer) for the delivery and sustained release of its compounds into the eye. Ideally the vessel/polymer should be:
• inducing minimal or no inflammatory response and should not lead to loss of photoreceptor cells
• tested in vivo
• result in sustained release of the compound
• function as a reservoir to reduce the number of injection
The compounds will be coupled to the delivery system and tested in relevant models for validation of the approach.
SMEs and pharma industries with an expertise in biopolymers and/or surface chemistry are being sought for drug formulation.
In the context of research agreements and/or technological cooperation, the companies are expected to provide matrices of biopolymers and/ or surface chemistry on which the compounds that modify microtubule biophysical properties of microtubules can be attached for appropriate and efficient drug delivery into the eye.